文献速递免疫规划传染病防控与疫情报告

6岁儿童加强免疫无细胞百白破疫苗保护效果的评估

[Evaluation of the protective effect of acellular DPT vaccine for booster immunization in 6-year-old children].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2025-01-01

该回顾性队列研究纳入960名6岁儿童,比较加强免疫第5剂无细胞百白破疫苗(DTaP)与白破疫苗(DT)后两年内百日咳发病情况。DTaP组报告发病率1.25%,DT组2.92%,疫苗保护效果(VE)为57.14%(95%CI:-10.59%~83.39%)。接种后6、12、18和24个月VE分别为100%、63.80%、64.59%和57.60%。

要点

  • 6岁加强DTaP对百日咳有一定保护效果,总体VE为57.14%(95%CI:-10.59%~83.39%)。
  • 接种后6个月VE为100%,12、18、24个月VE分别为63.80%、64.59%、57.60%。
  • DTaP组12~24个月人年累积发病率未呈明显上升或下降趋势(Z=-0.995,P=0.320)。

核心结论

  • 6岁儿童加强免疫DTaP对减少百日咳发病具有一定的保护效果,接种后早期(0~6个月)保护效果显著,12~24个月仍有保护效果。

研究设计与样本

  • 回顾性队列研究,共纳入960名6岁儿童,试验组480名加强免疫第5剂DTaP,对照组480名加强免疫DT,比较2023年5月至2025年5月百日咳发病情况。

主要发现

  • 试验组报告百日咳确诊病例6例,报告发病率1.25%;对照组报告14例,报告发病率2.92%。
  • DTaP对百日咳的保护效果(VE)为57.14%(95%CI:-10.59%~83.39%)。
  • 基于人年累积发病率,接种后6、12、18和24个月VE分别为100%、63.80%(95%CI:-14.49%~88.55%)、64.59%(95%CI:1.17%~87.31%)和57.60%(95%CI:-10.80%~83.78%)。
  • DTaP组12~24个月人年累积发病率未呈明显的上升或下降趋势(Z=-0.995,P=0.320)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the epidemiological protective effect of a booster dose of acellular DTP vaccine (DTaP) against pertussis in 6-year-old children. Methods: A retrospective cohort study was conducted to compare the incidence of pertussis in 6-year-old children who received DTaP versus DT vaccine boosters in 2023 over a two-year period from May 2023 to May 2025. The protective effect of the fifth dose of DTaP against pertussis in 6-year-old children was evaluated. Results: A total of 960 participants were enrolled in this study, including 480 children in the experimental group who received the fifth dose of DTaP vaccine and 480 children in the control group who received the DT vaccine booster. Baseline characteristics were balanced between the two groups. There were six confirmed cases of pertussis in the experimental group, with a reported incidence rate of 1.25%. In the control group, 14 pertussis cases were reported, with a reported incidence rate of 2.92%. The protective effectiveness(VE) of the DTaP vaccine against pertussis was 57.14% (95%CI:-10.59%-83.39%). For 6-year-old children who completed the booster immunization, the incidence data of pertussis were collected from the 14th day after vaccination (i.e., the study day 0). Based on the annual cumulative incidence rate, the VE of DTaP against pertussis at 6, 12, 18, and 24 months after vaccination was 100%, 63.80% (95%CI:-14.49%-88.55%), 64.59% (95%CI: 1.17%-87.31%), and 57.60% (95%CI:-10.80%-83.78%), respectively. In the DTaP group, the annual cumulative incidence rate of 12 to 24 months did not show a significant upward or downward trend (Z=-0.995, P=0.320). Conclusion: Boosting 6-year-old children with the DTaP vaccine provides measurable protection against pertussis. The protective efficacy is significant in the early stage (0 to 6 months) after vaccination, and it still remains effective at 12 to 24 months. 目的: 分析 6 岁儿童加强免疫无细胞百白破疫苗(DTaP)对百日咳的流行病学保护效果。 方法: 对2023年加强免疫 DTaP和白破疫苗(DT)的 6 岁儿童2023年5月至2025年5月的百日咳发病情况进行比较,利用回顾性队列研究方法评估6岁儿童加强第5剂DTaP对百日咳的保护效果。 结果: 共纳入研究对象960名,其中6岁加强免疫第5剂 DTaP 的试验组儿童480名,加强免疫DT的对照组儿童480名。试验组和对照组基线特征均衡可比。试验组共报告百日咳确诊病例 6 例,报告发病率为1.25%,对照组共报告百日咳确诊病例 14 例,报告发病率为2.92%,DTaP对百日咳的保护效果(VE)为57.14%(95%CI:-10.59%~83.39%)。对完成加强免疫后的 6 岁儿童从疫苗接种后的第 14 天(即研究第 0 天)开始收集百日咳发病数据,基于人年累积发病率计算,DTaP在接种后 6、12、18和 24 个月时对百日咳的VE分别为 100%、63.80%(95%CI:-14.49%~88.55%)、64.59%(95%CI:1.17%~87.31%)和57.60%(95%CI:-10.80%~83.78%)。DTaP组12~24个月的人年累积发病率未呈明显的上升或下降趋势(Z=-0.995,P=0.320)。 结论: 6 岁儿童加强免疫 DTaP 对减少百日咳发病具有一定的保护效果,接种后早期(0~6 个月)保护效果显著,12~24个月仍有保护效果。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Tang XW, Zhu Y, Yan R, et al. [Evaluation of the protective effect of acellular DPT vaccine for booster immunization in 6-year-old children]. Zhonghua Yu Fang Yi Xue Za Zhi. 2025. PMID: 41287323. doi:10.3760/cma.j.cn112150-20250701-00614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。